Possible Interaction: Methylselenocysteine and Irinotecan

“The in vivo synergy between MSC and irinotecan is influenced by treatment schedule and associated with enhancement of tumor vessel maturation, intra-tumor concentration of SN-38 and apoptotic death of tumor cells.”

“We have previously shown that 5-methylselenocysteine (MSC) enhances therapeutic efficacy of irinotecan in various human tumor xenografts.”

“We have reported that Se-methylselenocysteine (MSC) therapeutically enhances the efficacy and selectivity of irinotecan against human tumor xenografts.”

“ MSC is highly effective in modulating the therapeutic index of irinotecan.”

“Analysis of tumor tissues at 24 h after treatment with synergistic modality of irinotecan and MSC revealed significant downregulation of COX-2, inducible nitric oxide synthase (iNOS) and hypoxia-induced factor-1α expression (HIF 1α).”

“In FaDu xenografts, a poorly differentiated tumor-expressing mutant p53, the cure rate was increased from 30% with irinotecan alone to 100% with the combination of irinotecan and MSC.”

“Moreover, decreased microvessel density was observed after irinotecan treatment with the addition of MSC.”

“Therapeutic synergy between MSC and irinotecan was demonstrated by our laboratory in mice bearing human squamous cell carcinoma of the head and neck tumors.”

“The combination of methylselenocysteine and irinotecan (CPT-11) is synergistic against FaDu and A253 xenografts.”

“Results from this laboratory have demonstrated that MSC and SLM are highly effective modulators of irinotecan cure rates in de novo sensitive and resistant human tumor xenografts.”

“Studies in mice have documented that the minimum effective dose of MSC when combined with irinotecan is 0.01 mg daily.”